These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


116 related items for PubMed ID: 22513515

  • 1. Incidence of hypercalcemia, hypercalciuria and related factors in patients treated with recombinant human parathyroid hormone (1-84).
    Luna-Cabrera F, Justicia-Rull EA, Caricol-Pérez MP, Soler-Vizán E, Mesa-López CM, Ruiz-Ruiz MA, De La Torre-López LE.
    Minerva Med; 2012 Apr; 103(2):103-10. PubMed ID: 22513515
    [Abstract] [Full Text] [Related]

  • 2. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
    Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, Treatment of Osteoporosis with Parathyroid Hormone Study Group.
    Ann Intern Med; 2007 Mar 06; 146(5):326-39. PubMed ID: 17339618
    [Abstract] [Full Text] [Related]

  • 3. The effect of recombinant PTH(1-34) and PTH(1-84) on serum ionized calcium, 1,25-dihydroxyvitamin D, and urinary calcium excretion: a pilot study.
    Piemonte S, Romagnoli E, Cipriani C, Fassino V, Del Fiacco R, Carnevale V, Scillitani A, D'Erasmo E, Tancredi A, Minisola S.
    Calcif Tissue Int; 2009 Oct 06; 85(4):287-92. PubMed ID: 19756348
    [Abstract] [Full Text] [Related]

  • 4. Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
    Antoniucci DM, Sellmeyer DE, Bilezikian JP, Palermo L, Ensrud KE, Greenspan SL, Black DM.
    J Clin Endocrinol Metab; 2007 Mar 06; 92(3):942-7. PubMed ID: 17164314
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide.
    Miller PD, Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, Wong M, Marcus R.
    J Clin Endocrinol Metab; 2007 Sep 06; 92(9):3535-41. PubMed ID: 17609307
    [Abstract] [Full Text] [Related]

  • 7. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
    Anastasilakis AD, Polyzos SA, Avramidis A, Toulis KA, Papatheodorou A, Terpos E.
    Clin Endocrinol (Oxf); 2010 Jun 06; 72(6):752-7. PubMed ID: 19832854
    [Abstract] [Full Text] [Related]

  • 8. Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis.
    Schafer AL, Palermo L, Bauer DC, Bilezikian JP, Sellmeyer DE, Black DM.
    J Clin Densitom; 2011 Jun 06; 14(1):68-73. PubMed ID: 21095149
    [Abstract] [Full Text] [Related]

  • 9. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S.
    J Bone Miner Res; 2001 Jan 06; 16(1):113-9. PubMed ID: 11149474
    [Abstract] [Full Text] [Related]

  • 10. [Increase of PTH in post-menopausal osteoporosis].
    Cerdà D, Peris P, Monegal A, Albaladejo C, Martínez de Osaba MJ, Surís X, Guañabens N.
    Rev Clin Esp; 2011 Jan 06; 211(7):338-43. PubMed ID: 21596374
    [Abstract] [Full Text] [Related]

  • 11. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.
    Garnero P, Cloos P, Sornay-Rendu E, Qvist P, Delmas PD.
    J Bone Miner Res; 2002 May 06; 17(5):826-33. PubMed ID: 12009013
    [Abstract] [Full Text] [Related]

  • 12. The course of hypercalciuria and related markers of bone metabolism parameters associated with corticosteroid treatment.
    Duzen O, Erkoc R, Begenik H, Soyoral YU, Aldemir MN.
    Ren Fail; 2012 May 06; 34(3):338-42. PubMed ID: 22260330
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun 06; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

  • 14. [Severe osteoporosis treatment with teriparatide].
    Sarli MA, Zanchetta MB, Rey PG, Spivacow FR.
    Medicina (B Aires); 2013 Jun 06; 73(5):428-32. PubMed ID: 24152398
    [Abstract] [Full Text] [Related]

  • 15. Summaries for patients. Parathyroid hormone (1-84) and risk for spinal fractures in women with osteoporosis.
    Ann Intern Med; 2007 Mar 06; 146(5):I20. PubMed ID: 17339614
    [No Abstract] [Full Text] [Related]

  • 16. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.
    Hansdóttir H, Franzson L, Prestwood K, Sigurdsson G.
    J Am Geriatr Soc; 2004 May 06; 52(5):779-83. PubMed ID: 15086661
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Decreased serum osteocalcin levels in patients with postmenopausal osteoporosis.
    Pietschmann P, Resch H, Krexner E, Woloszczuk W, Willvonseder R.
    Acta Med Austriaca; 1991 May 06; 18(5):114-6. PubMed ID: 1796722
    [Abstract] [Full Text] [Related]

  • 19. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
    Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM.
    J Clin Invest; 1993 Mar 06; 91(3):1138-48. PubMed ID: 8450043
    [Abstract] [Full Text] [Related]

  • 20. A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China.
    Zhang XZ, Wang B, Yang J, Xuan M, Song LG, Li H, Guo XH, Lü XF, Xue QY, Yang GY, Ji QH, Shen J, Liu ZM, Li CJ, Wu TF, Tong XC, Jia Y.
    Chin Med J (Engl); 2009 Dec 20; 122(24):2933-8. PubMed ID: 20137477
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 6.